SLC5A2 and type 2 diabetes mellitus: In cases of patients who suffer from DM, new anti-diabetic, sodium-glucose cotransporter-2 (SGLT2) inhibitors have significant value in slowing down the progression of kidney disease in patients with type 2 diabetes [88].